Toward HIV eradication or remission: the tasks ahead.

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25

Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol (1999) 3.79

Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci U S A (2003) 3.47

Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol (1999) 3.15

Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A (1999) 3.00

Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol (2002) 2.63

Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest (2000) 2.21

Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis (2012) 2.00

Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines. J Virol (1998) 1.93

Efficient virus extinction by combinations of a mutagen and antiviral inhibitors. J Virol (2001) 1.86

Common elements in self-management of HIV and other chronic illnesses: an integrative framework. AIDS Care (2009) 1.81

OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol (2001) 1.75

Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. Proc Natl Acad Sci U S A (2003) 1.58

Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis (2014) 1.51

Viral blip dynamics during highly active antiretroviral therapy. J Virol (2003) 1.51

Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol (2009) 1.49

Replication-competent rhabdoviruses with human immunodeficiency virus type 1 coats and green fluorescent protein: entry by a pH-independent pathway. J Virol (1999) 1.43

Primary cell model for activation-inducible human immunodeficiency virus. J Virol (2007) 1.10

Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection. J Virol (2004) 1.06

Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. Math Biosci (2008) 1.05

Definition of the stage of host cell genetic restriction of replication of human immunodeficiency virus type 1 in monocytes and monocyte-derived macrophages by using twins. J Virol (1999) 1.03

Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. Retrovirology (2012) 0.99

Susceptibilities of simian immunodeficiency virus to protease inhibitors. Antimicrob Agents Chemother (2003) 0.95

Rational design of drugs that induce human immunodeficiency virus replication. J Virol (2003) 0.93

Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART. Proc Natl Acad Sci U S A (1998) 0.92

Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level. PLoS One (2013) 0.90

Transfer of human CD4(+) T lymphocytes producing beta interferon in Hu-PBL-SCID mice controls human immunodeficiency virus infection. J Virol (1999) 0.83

Genetic modification of hematopoietic stem cells as a therapy for HIV/AIDS. Viruses (2013) 0.80

Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis. Microbiol Mol Biol Rev (2000) 0.78

Mouse serum factor(s) down-modulate the CD4 and CXCR4 molecules on human T cells conferring resistance to HIV infection in NOG mice. Med Microbiol Immunol (2005) 0.76